For research use only
| Cat No. | ABC-TC002F |
| Product Type | Mouse Colon Cancer Cell Lines |
| Cell Type | Fibroblast |
| Species | Mouse |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Colon |
| Disease | Carcinoma |
| Product Code | CT26-OVA, CT26 OVA-expressing cells, CT26-OVA colon carcinoma cells, CT26 ovalbumin variant, OVA-transfected CT26 |
The CT26-OVA cell line is a modified version of the CT26 cell line, engineered to express the ovalbumin (OVA) antigen.
The CT26-OVA cell line is a variant of the CT26 murine colon carcinoma cell line that has been engineered to stably and highly express ovalbumin (OVA), a well-known immunogenic antigen protein.
In studies, the expression of OVA in CT26-OVA cells has been shown to increase their recognition by OVA-specific cytotoxic T-lymphocytes (CTLs). The CTLs recognize OVA fragments presented on MHC class I molecules, leading to targeted killing of the tumor cells. Additionally, research has demonstrated that CT26-OVA tumors exhibit a higher sensitivity to immune checkpoint inhibitors, such as anti-PD-1 therapy, compared to their parental CT26 counterparts.
Why choose CT26-OVA from AcceGen?
Choose CT26-OVA from AcceGen for its guaranteed mycoplasma-free status, ensuring contamination-free research. We offer quick delivery and ship on dry ice to maintain cell viability. Additionally, the cell line is STR-identified for authenticity, providing reliable, high-quality cells for your immuno-oncology studies.
| Product Code | CT26-OVA, CT26 OVA-expressing cells, CT26-OVA colon carcinoma cells, CT26 ovalbumin variant, OVA-transfected CT26 |
| Species | Mouse |
| Cat.No | ABC-TC002F |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Fibroblast |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Colon |
| Disease | Carcinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Colon Cancer Cell Lines |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
The CT26-OVA cell line is a valuable tool in immuno-oncology research, offering a robust model for studying immune responses and evaluating cancer therapeutics. Engineered to stably express the highly immunogenic ovalbumin (OVA) antigen, CT26-OVA cells enhance tumor-immune interactions, making them ideal for screening immunotherapies. These cells can establish tumors in vivo, enabling efficacy studies in animal models, particularly for immune checkpoint inhibitors like anti-PD-1. Researchers can use CT26-OVA to explore antigen presentation, cytotoxic T-lymphocyte (CTL) recognition, and tumor cell death, providing insights into mechanisms of immune evasion and the development of novel cancer treatments. This cell line serves as a powerful platform for advancing the field of cancer immunotherapy.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
